Obserwuj
Tadeusz Robak
Tadeusz Robak
Profesor, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
Zweryfikowany adres z csk.umed.lodz.pl
Tytuł
Cytowane przez
Cytowane przez
Rok
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
19292014
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
17072015
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ...
Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018
16132018
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ...
The lancet oncology 12 (5), 431-440, 2011
11792011
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ...
New England Journal of Medicine 378 (12), 1107-1120, 2018
9472018
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ...
Annals of Oncology 32 (1), 23-33, 2021
9002021
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani, MB Agarwal, ...
Blood, The Journal of the American Society of Hematology 119 (5), 1123-1129, 2012
7922012
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ...
Journal of Clinical Oncology 28 (10), 1749, 2010
7882010
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy …
RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ...
Journal of Clinical Oncology 25 (25), 3892-3901, 2007
7822007
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
SJ Whittaker, MF Demierre, EJ Kim, AH Rook, A Lerner, M Duvic, ...
J Clin Oncol 28 (29), 4485-4491, 2010
7512010
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
P Hillmen, AB Skotnicki, T Robak, B Jaksic, A Dmoszynska, J Wu, ...
Journal of Clinical Oncology 25 (35), 5616-5623, 2007
7362007
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic …
T Robak, A Dmoszynska, P Solal-Céligny, K Warzocha, J Loscertales, ...
Journal of clinical oncology 28 (10), 1756-1765, 2010
6102010
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ...
Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 2007
5392007
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith, T Robak, ...
Leukemia 33 (2), 379-389, 2019
4972019
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
B Coiffier, S Lepretre, LM Pedersen, O Gadeberg, H Fredriksen, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1094-1100, 2008
4952008
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ...
Leukemia 34 (3), 787-798, 2020
4802020
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
T Robak, H Huang, J Jin, J Zhu, T Liu, O Samoilova, H Pylypenko, ...
New England Journal of Medicine 372 (10), 944-953, 2015
4252015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label …
P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ...
The Lancet 385 (9980), 1873-1883, 2015
4192015
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ...
Journal of clinical oncology 39 (31), 3441, 2021
4082021
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
RJ Kreitman, MS Tallman, T Robak, S Coutre, WH Wilson, ...
Journal of Clinical Oncology 30 (15), 1822, 2012
3902012
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20